Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Eletriptan review.

Markus Färkkilä1, Mikko Kallela

  • 1Department of Neurology, University Hospital Haartmaninkatu 4, 00290 Helsinki, Finland. markus.farkkila@hus.fi

Expert Opinion on Pharmacotherapy
|June 7, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Kinetic Oscillation Stimulation for the Preventive Treatment of Chronic Migraine: A Randomized, Double-Blind, Sham-Controlled Trial.

Neurology·2025
Same author

<i>NCOR2</i> is a novel candidate gene for migraine-epilepsy phenotype.

Cephalalgia : an international journal of headache·2022
Same author

Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles.

Nature genetics·2022
Same author

Polygenic risk provides biological validity for the ICHD-3 criteria among Finnish migraine families.

Cephalalgia : an international journal of headache·2021
Same author

Electrocardiographic findings in migraineurs: results of the Finnish Health 2000 survey.

Acta neurologica Scandinavica·2021
Same author

Left ventricular hypertrophy and other cardiac risk factors in migraineurs.

Acta neurologica Scandinavica·2021
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Eletriptan, a serotonin 5-HT(1B/1D)-receptor agonist, effectively treats acute migraine with rapid absorption and long plasma half-life. It demonstrates superior efficacy compared to other migraine treatments in clinical trials.

Area of Science:

  • Pharmacology
  • Neurology
  • Clinical Trials

Background:

  • Eletriptan is a selective serotonin 5-HT(1B/1D)-receptor agonist.
  • It is rapidly absorbed and possesses a long plasma half-life.
  • Eletriptan has demonstrated efficacy and tolerability in acute migraine treatment.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of eletriptan in acute migraine.
  • To compare eletriptan with other migraine treatments, including sumatriptan, zolmitriptan, naratriptan, and ergotamine/caffeine.
  • To assess long-term response and efficacy in difficult-to-treat migraine patients.

Main Methods:

  • Randomized, double-blind, placebo-controlled acute migraine trials.
  • Long-term open-label trials.

Related Experiment Videos

  • Head-to-head trials comparing eletriptan with other migraine medications.
  • Meta-analysis of triptan trials.

    • Main Results:

    • Eletriptan shows consistent response across multiple attacks and up to 1 year of use.
    • Head-to-head trials indicate better efficacy than sumatriptan, zolmitriptan, naratriptan, and ergotamine/caffeine, with similar adverse events.
    • A meta-analysis showed eletriptan 80 mg had better efficacy but lower tolerability than sumatriptan 100 mg.
    • Eletriptan is effective in patients dissatisfied with prior migraine treatments.

    Conclusions:

    • Eletriptan is an effective and well-tolerated acute migraine treatment.
    • It offers superior efficacy compared to several other migraine medications.
    • Eletriptan provides a valuable treatment option, particularly for patients with inadequate response to other therapies.